Seasonal Allergic Rhinitis

Oncology·MeSH: Rhinitis, Allergic, Seasonal

Prevalence

20000.0 / 100K

Incidence

2000.0 / 100K/yr

12 drugs in development·6 companies·4 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
azelastine	Amneal Pharmaceuticals, Inc. (AMRX)
desloratadine	PERRIGO Co plc (PRGO)
olopatadine	Amneal Pharmaceuticals, Inc. (AMRX)
triamcinolone acetonide	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(5)

Drug	Company
fexofenadine	Sanofi (SNY)
Fexofenadine	Sanofi (SNY)
pg-011 nasal spray 0.6%	TG THERAPEUTICS, INC. (TGTX)
pumecitinib nasal spray 0.6%	TG THERAPEUTICS, INC. (TGTX)
TQC2938 injection	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2(1)

Drug	Company
pumecitinib nasal spray 0.3%	TG THERAPEUTICS, INC. (TGTX)

Phase 4(2)

Drug	Company
Fexofenadine HCL and pseudoephedrine HCL	Sanofi (SNY)
Rezafungin for Injection	Crinetics Pharmaceuticals, Inc. (CRNX)

BioSniper tracks 12 drugs in development for Seasonal Allergic Rhinitis across 6 companies.

There are 4 clinical trials targeting Seasonal Allergic Rhinitis tracked by BioSniper.

The estimated prevalence of Seasonal Allergic Rhinitis is approximately 20000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.